Clinical Trials

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT05888402 2026-02-27

InTRist

50 enrolled

Local Advanced Non-small Cell Lung Cancer

NCT04418648 2026-02-04

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Phase 2 Terminated

170 enrolled

Small Cell Lung Cancer Limited Stage

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07309276 2025-12-30

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

864 enrolled

Advanced Lung Cancer

NCT07308379 2025-12-29

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

Not yet recruiting

1,200 enrolled

Phase 2 Active not recruiting

SCLC, Extensive Stage

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

40 enrolled

Non-small Lung Cancer

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

119 enrolled

Advanced Lung Cancer

NCT07251582 2025-11-26

LungTime-C02

Phase 3 Recruiting

156 enrolled

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT06127303 2025-09-05

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07039656 2025-08-07

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

211 enrolled

Stage IB-IIIB NSCLC

NCT07097948 2025-08-01

Adjuvant

40 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT06437977 2025-03-13

neoR-TORCH

Phase 3 Recruiting

478 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05000684 2025-02-20

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Phase 1/2 Completed

67 enrolled

Phase 1 Not yet recruiting

Advanced Lung Cancer

NCT06732258 2024-12-27

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

12 enrolled

Small Cell Lung Carcinoma

NCT03623776 2024-12-06

NAJSCR

Phase 2 Withdrawn

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06269211 2024-11-18

TOPLINE

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06648200 2024-10-18

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

100 enrolled

Recurrence, Small Cell Lung Carcinoma

NCT04144608 2024-08-09

TOGATHER

Phase 2 Completed

40 enrolled

Advanced Non Small Cell Lung Cancer

NCT06095583 2024-06-21

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Phase 3 Recruiting

756 enrolled

Small Cell Lung Carcinoma

NCT06256237 2024-05-29

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Small Cell Lung Carcinoma

NCT04238169 2024-02-28

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Phase 2 Completed

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06065813 2023-10-04

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

126 enrolled

Non Squamous Non Small Cell Lung Cancer

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Phase 1 Unknown

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT05800340 2023-04-05

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Carcinoma, Non-Small-Cell Lung

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

27 enrolled

High-Risk Resectable NSCLC

NCT03856411 2023-02-01

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Phase 3 Completed

465 enrolled

Treatment-naive Advanced Non-small Cell Lung Cancer

NCT05652712 2022-12-15

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Unknown

200 enrolled

Lung Neoplasms

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Small Cell Lung Carcinoma

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04304248 2021-05-06

NeoTAP01

Carcinoma, Non-Small-Cell Lung

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04797702 2021-03-15

CT32

Phase 1/2 Unknown

67 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

341 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04731909 2021-02-10

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase NA Unknown

80 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04193098 2020-07-07

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Phase 1 Unknown

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled